1. Combination of aztreonam, ceftazidime-avibactam and amikacin in the treatment of VIM-1 Pseudomonas aeruginosa ST235 osteomyelitis.
- Author
-
Mularoni A, Mezzatesta ML, Pilato M, Medaglia AA, Cervo A, Bongiorno D, Aprile A, Luca A, Stefani S, and Grossi P
- Subjects
- Aged, Debridement, Drug Combinations, Drug Resistance, Multiple, Bacterial genetics, Drug Therapy, Combination, Female, Humans, Osteomyelitis microbiology, Osteomyelitis surgery, Pseudomonas Infections surgery, Amikacin therapeutic use, Anti-Bacterial Agents therapeutic use, Azabicyclo Compounds therapeutic use, Aztreonam therapeutic use, Ceftazidime therapeutic use, Osteomyelitis drug therapy, Pseudomonas Infections drug therapy, Pseudomonas aeruginosa
- Abstract
We describe a challenging case of patient with metallo-beta-lactamase-producing Pseudomonas aeruginosa sternal osteomyelitis following aortic valve replacement with biological prosthesis. The strain exhibited a multidrug-resistance phenotype carrying the bla
VIM-1 gene and belonged to the high-risk clone sequence type ST235. The patient was successfully treated with surgical debridement plus antibiotic therapy with ceftazidime/avibactam, aztreonam, and amikacin. Time-kill curves showed that this triple antibiotic combination at 1 × MIC was strongly synergic after 8 h, achieving 99.9% killing and maintaining this until 48 h., (Copyright © 2021. Published by Elsevier Ltd.)- Published
- 2021
- Full Text
- View/download PDF